Oxford Biomedica PLC Strategic Alliance with Orchard Therapeutics (3629Q)
November 29 2016 - 02:01AM
UK Regulatory
TIDMOXB
RNS Number : 3629Q
Oxford Biomedica PLC
29 November 2016
Oxford BioMedica Announces a Strategic Alliance with Orchard
Therapeutics
Oxford, UK & London, UK- 29 November 2016: Oxford BioMedica
plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene
and cell therapy group, today announces it has entered into a
strategic alliance with Orchard Therapeutics ("Orchard"), a
biotechnology company dedicated to bringing transformative ex-vivo
stem cell based gene therapies to patients with serious and
life-threatening orphan diseases.
As part of the agreement the Group will develop and supply
lentiviral vectors used by Orchard for the manufacture of ex-vivo
gene therapy products in primary immune deficiency disorders and
inherited metabolic disorders, including adenosine deaminase severe
combined immunodeficiency (ADA-SCID), Mucopolysaccharidosis-IIIA
(MPS-IIIA or Sanfilippo Syndrome type A) and undisclosed follow-on
indications. Orchard will lead the global clinical development and
commercialisation of collaboration programmes in Europe, the United
States and in other regions.
Under the terms of the collaboration and licence agreement,
Oxford BioMedica will receive a 1.95% equity stake in Orchard and
will be entitled to royalties on future sales of products covered
by the collaboration. The Group will provide process development
services and manufacture clinical and commercial GMP-grade
lentiviral vectors for Orchard. The process development
arrangements include performance-related incentives through which
Oxford BioMedica could receive a further 1.95% equity stake in
Orchard. The Group has also granted an exclusive intellectual
property licence to Orchard for collaboration programmes.
John Dawson, Chief Executive Officer of Oxford BioMedica,
commented: "We are delighted to initiate a Strategic Alliance with
Orchard Therapeutics and look forward to working with them to
develop and launch much needed treatments for patients in desperate
need of better treatment options. The alliance combines Oxford
BioMedica's world-leading capabilities in lentiviral vector process
development and bioprocessing expertise with Orchard's expertise in
the development and commercialisation of gene therapies for orphan
diseases. This further demonstrates Oxford BioMedica's position as
a "go to" partner for companies and academic institutions working
with lentiviral vector based products."
Stewart Craig, Chief Manufacturing Officer of Orchard
Therapeutics Ltd., commented: "Orchard is a leader in bringing
transformative gene therapies to patients with serious and life
threatening orphan diseases. This alliance with Oxford BioMedica
represents a key element of the supply chain for manufacture of our
ex vivo gene-modified stem cell products. We expect that Oxford
BioMedica's expertise in the development and manufacture of
lentiviral vectors, along with their proven experience of working
with global pharma companies will accelerate our ability to
potentially address a series of devastating genetic diseases. We
are excited about the potential for this alliance to deliver real
patient benefits."
-Ends-
For further information,
please contact:
Oxford BioMedica plc: Tel: +44 (0)1865
John Dawson, Chief Executive 783 000
Officer
Tim Watts, Chief Financial
Officer
Financial and corporate communications Tel: +44 (0)20 3709
enquiries: 5700
Consilium Strategic Communications
Mary-Jane Elliott/Matthew
Neal/Chris Welsh/Laura Thornton
Orchard Therapeutics Limited:
Sylvie Blanchier Tel: +44 (0)20 3823 2149
Notes to editors
About Oxford BioMedica(R)
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy
company focused on developing life changing treatments for serious
diseases. Oxford BioMedica and its subsidiaries (the "Group") have
built a sector leading lentiviral vector delivery platform
(LentiVector(R) ) through which the Group develops in vivo and
ex-vivo products both in-house and with partners. The Group has
created a valuable proprietary portfolio of gene and cell therapy
product candidates in the areas of oncology, ophthalmology and CNS
disorders. The Group has also entered into a number of
partnerships, including with Novartis, Sanofi, GSK, and Immune
Design, through which it has long-term economic interests in other
potential gene and cell therapy products. Oxford BioMedica is based
across several locations in Oxfordshire, UK and employs more than
250 people. Further information is available at
www.oxfordbiomedica.co.uk.
About Orchard Therapeutics Ltd.
Orchard Therapeutics is a clinical-stage biotechnology company
dedicated to bringing transformative ex-vivo gene therapies to
patients with serious and life-threatening orphan diseases. The
company was recently named a Fierce 15 Company for 2016 by Fierce
Biotech. For more information, visit www.orchard-tx.com
About Adenosine Deaminase Deficiency Severe Combined
Immunodeficiency ("ADA-SCID")
ADA-SCID is a rare inherited disorder of the immune system. The
incidence of ADA-SCID is estimated between 1 in every 375,000 -
660,000 live births, according to literature sources. ADA-SCID is
caused by mutations in the gene encoding for the enzyme adenosine
deaminase, which result in a severe deficiency in white blood cells
and life-threatening infections. In the absence of treatment,
ADA-SCID is fatal within the first months of life. Despite
currently available treatment options, there remains significant
need for therapies that reduce the mortality, morbidity and burden
of disease on patients and families.
About Mucopolysaccharidosis type-A (Sanfilippo Syndrome type
A)
Mucopolysaccharidosis type-A is a rare neurodegenerative
lysosomal storage disease caused by mutations in the
sulfoglycosamine sulfohydrolase (SGSH) gene. There are no effective
treatments for MPS-IIIA to date. The disease affects children in
early life, with a progressive decline in cognitive and behavioural
function and a subsequent decline in motor function and results in
severe dementia and early death, usually in the teens or early
twenties.
This information is provided by RNS
The company news service from the London Stock Exchange
END
ALLLFFEFLRLTFIR
(END) Dow Jones Newswires
November 29, 2016 02:01 ET (07:01 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Feb 2024 to Mar 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Mar 2023 to Mar 2024